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Abstract
Background: Neuropeptide Y (NPY) is an important central orexigenic hormone predominantly produced by the
hypothalamus, and recently found to be secreted in adipose tissue (AT). Acipimox (Aci) inhibits lipolysis in AT and
reduces plasma glycerol and free fatty acid (FFA) levels. Exercise and Aci are enhancers of growth hormone (GH)
and NPY secretion and exercise may alter leptin levels. We expect to find abnormal neuropeptidergic response in
plasma and AT in patients with bulimia nervosa (BN). We hypothesize that Aci influences these peptides via a FFA-
independent mechanism and that Aci inhibits lipolysis through a cyclic adenosine monophosphate (cAMP)-
dependent pathway. Dysregulations of the AT-brain axis peptides might be involved in binge eating as is the case
in BN.
Methods: The objective of this study was to determine the responses of plasma NPY, GH, leptin, FFA and glycerol
levels to exercise in BN patients and healthy women (C) given the anti-lipolytic drug Aci or placebo. The secondary
objective of this study was to compare the responses of extracellular glycerol levels and plasma glycerol levels to
exercise alone or together with Aci administration in BN patients and C women. Extracellular glycerol was
measured in vivo in subcutaneous (sc) abdominal AT using microdialysis. Eight BN and eight C women were
recruited for this single-blind, randomized study. Aci or placebo was given 1 hour before the exercise (45 min, 2
W/kg of lean body mass [LBM]). NPY, GH, leptin, FFA, glycerol plasma and AT glycerol levels were measured using
commercial kits.
Results: The primary outcome of this study was that the exercise with Aci administration resulted in plasma NPY
and GH increase (after a 45-minute exercise) and leptin (after a 90-minute post-exercise recovering phase)
increased more in BN patients. The secondary outcomes of this study were that the exercise with Aci
administration induced a higher decrease of extracellular glycerol in BN patients compared to the C group, while
the exercise induced a higher increase of glycerol concentrations in sc abdominal AT of BN patients. Plasma
glycerol levels decreased more in BN patients and plasma FFA levels were depressed in both groups after the
exercise with Aci administration. The exercise induced similar increases in plasma NPY, GH, FFA and glycerol levels,
and a similar decrease in the plasma leptin level in both groups.
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any medium, provided the original work is properly cited.Conclusions: We confirm the results of a single-blind, randomized, microdialysis study, i.e. that the Aci-induced
elevation in plasma NPY and GH levels during the exercise is higher in BN patients and that Aci increased plasma
leptin levels in the post-exercise recovering phase (90-minute) more in BN patients. The post-exercise rise (45-
minute) in AT glycerol is much more attenuated by acute Aci treatment in BN patients. Simultaneously, we found
facilitated turnover of plasma glycerol after the exercise together with Aci administration in BN. Our results support
the hypotheses that Aci exerts an effect on the FFA-independent and cAMP-dependent mechanism.
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Background
Bulimia nervosa (BN) is an eating disorder characterized
by repeated episodes of binge eating followed by inap-
propriate compensatory behavior with no pathological
change in body weight, leading to so far poorly under-
stood neuroendocrine dysfunction of the hypothalamic-
pituitary-adrenal axis [1]. Neuropeptide Y (NPY) is
expressed predominantly in the neurons of the hypotha-
lamic arcuate nucleus and co-exists with catecholamines
in the central and the sympathetic nervous system
(SNS), which play an important role in the up- or
down-regulation of adipose tissue (AT) lipolysis [2].
Moreover, NPY receptors are highly expressed on
human adipocytes where they inhibit lipolysis [3].
Recently, it was found that NPY is synthesized in
human AT and stimulates proliferation and differentia-
tion of new adipocytes [4], and that adipose-derived
NPY may have implications for central feedback of adip-
osity signals.
Both fasting and exercise are catabolic stress states
during which secretion of growth hormone (GH)
increases and activation of the GH secretagogue recep-
tors (GHSR), abundantly expressed in the arcuate
nucleus, up-regulates expression of NPY [5,6]. It has
been reported that NPY can attenuate specific behavior
when the organism is stressed and anti-stress effects of
NPY are relevant to psychiatric conditions such as anor-
exia nervosa (AN) and BN [7,8].
Physical exercise and anti-lipolytic drugs are well-
recognized stimulators of several hormones, such as GH
and NPY [5,9,10], however, molecular mechanisms and
receptor array underlying these regulations are different
and remain unidentified [10-14]. Even though plasma
NPY levels do not reflect NPY secretion in the brain,
there is not a clear evidence that plasma NPY levels ori-
ginate from peripheral sympathetic nerve secretion or
the adrenal gland and/or AT during exercise in humans
[15].
In our recent study, we reported increased response of
GH and ghrelin to exercise and anti-lipolytic drug
administration in BN patients, and we confirmed that
GH exerted an inhibitory feedback effect on plasma
ghrelin during exercise only in BN patients; however,
this effect was exerted in both BN patients and healthy
women during exercise with Acipimox (Aci) administra-
tion [16].
Recent experimental evidence suggests that plasma
NPY is increased in low plasma leptin states, and that
plasma leptin levels are negatively correlated with NPY
in patients with AN [17]. Furthermore, leptin is involved
in the control of glucose-lipid homeostasis, energy sto-
rage and multiple neuroendocrine functions, which are
impaired in BN and AN patients, including the patholo-
gical adaptation of the organism to starvation [18,19]. It
is possible that the malnutrition-dependent reduction of
leptin levels may play a role in the hypersomatotropism
of AN [20,21]. This GH secretory pattern, which may
reflect an adaptive phenomenon, is favoring the prefer-
ential utilization of free fatty acids (FFA). Indeed, we
have previously shown that anorectic patients have a
higher rate of lipolysis relative to healthy women [22]. It
has been suggested that fasting and exercise-enhanced
appetite and food intake are due to an increased nega-
tive energy balance, causing a change of the levels of
some hypothalamic and extra-hypothalamic peptides
such as NPY. Karamouzis et al [9] examined the effect
of intense prolonged exercise on plasma leptin and NPY
levels in man. This indicates that low level of leptin
facilitates expression of NPY synthesis. The effect of
exercise on decreased plasma leptin is suggested via
increased plasma FFA levels [23], although direct action
of FFA on plasma leptin levels cannot be concluded
[24]. However, leptin production was stimulated by the
anti-lipolytic agent Aci from isolated rat adipocytes [25].
On the basis of our previous study [16] we expect to
find abnormal neuropeptidergic response in plasma and
AT in BN patients. We hypothesize that plasma NPY,
GH and leptin levels induced by the exercise together
with Aci administration are not mediated by FFA.
Leptin-NPY-GH interactions and the role of appetite-
regulating neuropeptides in mediating lipolysis in
humans are not well understood. Dysregulations of the
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pathogenesis of BN patients [16,26,27]. In this eating
disorder characterized by repeated episodes of binge eat-
ing followed by inappropriate compensatory behavior,
increased baseline plasma GH and NPY levels were
documented, similarly as in restrictive-type AN patients
with low body mass index (BMI) [20,28,29].
Aci is a potent and long-acting anti-lipolytic drug,
derived from niacin. The inhibition of adipocyte lipolysis
by Aci is mediated through suppression of intracellular
cyclic adenosine monophosphate (cAMP) levels, which
inhibit adipocyte lipases such as hormone-sensitive
lipase (HSL) and the adipose triglyceride lipase (ATGL,
i.e. desnutrin) via alternative cAMP-independent path-
ways [25,30-32], thereby lowering circulating plasma
FFA and glycerol levels. We hypothesize that Aci influ-
ences inhibition of adipocyte lipolysis via the cAMP-
dependent mechanism.
The primary aim of this study was to examine the
changes in plasma NPY, GH, leptin, insulin, blood glu-
cose, FFA and glycerol levels induced by physical exer-
cise alone or in association with anti-lipolytic drug Aci
administration in BN patients and healthy women. The
secondary aim of this study was to compare the
responses of AT glycerol and plasma glycerol to exercise
alone or together with Aci administration in BN
patients. Healthy women were used as the control
group.
Subjects and Methods
The study was performed in accordance with the
Declaration of Helsinki and was approved by the Ethics
Committee of the Institute of Endocrinology in Prague.
Each participant signed an informed consent form
before entering the study. The study took place in the
Laboratory of Clinical nd Experimental Neuroendocrio-
nology of the Institute of Endocrinology in Prague from
January 2008 to June 2009. The study is registered at
Anzctr.org.au, ACTR Number: ACTRN12611000955910.
Patients and healthy women
Eight women with BN (means ± S.E.M., age: 24.33 ±
1.38 years; BMI: 20.63 ± 0.80 kg/m
2; percentage of body
fat [% BF]: 24.83 ± 1.92) and eight healthy women (age:
25.83 ± 1.69 years; BMI: 19.98 ± 0.44 kg/m
2; % BF: 24.5
± 0.47) were recruited for this study. All subjects
included in the study were nonsmokers, had no allergies
and had been free of medications for at least two weeks
prior to the study. Healthy volunteers had no history of
cardiovascular disease, eating disorders or other psychia-
tric diseases. All healthy women were in the first two
weeks of the follicular phase of their menstrual cycle.
Patients with BN were diagnosed according to the 4
th
edition of the Diagnostic and Statistical Manual of
Mental Disorders, American Psychiatric Association,
1994 [33]. All BN patients were clinically stable and in
relatively good health, except for their eating disorder.
In BN patients, the average frequency of binge-purging
episodes was 2.5 times per day over the last three-
month period and the average duration of their eating
disorder was 6 years and 8 months. They were investi-
gated after 1 week of hospitalization at the Department
of Psychiatry of the Charles University, Prague. Main
inclusion criteria were: age between 18 and 30 years,
BMI between 18 and 23 kg/m
2, patients with a diagnosis
of BN [33]. Women with diabetes type 1 or 2, hypo- or
hyperthyreoidism, cardiovascular disease, pregnant or
lactating women, patients with any severe active infec-
tion or cancer, patients with impaired mental capacity
or other psychiatric diseases were not eligible for partici-
pation in the study. Other exclusion criteria were:
hypertension, abnormal blood tests with significant
hyperlipidaemia, history or presence of hepatic or renal
disorders. For two weeks before the study they had to
refrain from taking anti-depressant and contraceptive
drugs. For five days before study they had to refrain
from taking aspirin, anti-histamine drugs and Tylenol
(acetaminophen). Two days before study they had to
avoid non herb tea, coffee (even decaffeinated), alcohol,
chocolate, cocoa, nuts, and bananas, and avoid smoking.
All subjects starved overnight with the exception of
drinking water. From all bulimic patients (14) and
healthy women (10), 8 BN patients and 8 healthy
women were acceptable during the inclusion procedure
(the recruitment phase in the Institute of Endocrinol-
ogy) for being randomized, i.e. 3 BN patients were
excluded, 1 BN patient did not meet inclusion criteria, 2
BN patients declined to participate in the study, 1
healthy woman did not meet inclusion criteria and 1
healthy woman declined to participate in this study. For
allocation of all particip a n t s( 8B Np a t i e n t sa n d8
healthy women) in the Institute of Endocrinology, a
computer-generated list of random numbers was used.
Our study used the allocation ratio 1:1 for two groups.
Experimental protocol and blood sampling
Blood tests conducted before initiation of the study con-
firmed normal values for blood count, fasting blood glu-
cose, and liver and renal function. All subjects
consumed a standardized low-fat dinner (468 kcal [1955
kJ], 5-g fat, 70-g carbohydrate and 25-g protein) at 6:00
PM and were then refrained from eating overnight.
Reported duration of sleep in the night preceding blood
sampling was comparable in all studied subjects. Sub-
j e c t sw e r ea d m i t t e dt ot h eI n s t i t u t eo fE n d o c r i n o l o g ya t
7:00 AM. After a short medical examination (blood
pressure, heart, and respiratory rate measurement, elec-
trocardiogram [ECG]), % BF was estimated by
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(TANITA, Tokyo, Japan). Before starting the test, all
individuals rested on the bed for 45 minutes. The pla-
cebo was matched to the study drug Aci for taste, color,
and size, and contained microcrystalline cellulose, iden-
tical in appearance but without the active ingredient.
Each woman was assigned a serial number and received
four capsules in two bottles. All subjects were rando-
mized according to a computer generated randomisation
list to receive either placebo or Aci capsules each week
(two 250 mg capsules of the acute-bolus Aci therapy or
placebo; 500 mg total - 5-Methylpyrazine-2-carboxylic
acid 4-oxide, molecular weight: 154.1, Olbetam capsules,
Farmitalia Carlo Erba, Milan, Italy) 1 hour before a sin-
gle exercise bout, once a week over a total of 2 weeks.
A low- to moderate-intensity exercise bout on an elec-
tromagnetically braked bicycle ergometer (Cateye EC
1600, Japan) was performed for 45 min at power output
2 W/kg of lean body mass (LBM) and the average pedal
speed was 60 revolutions per minute, intended to be
below the aerobic-anaerobic threshold. ECG, heart rate
and blood pressure were monitored using an Eagle 3000
cardiomonitor (Marquette, Milwaukee, WI, USA) and
haemodynamic parametres were measured every 5 min-
utes during the 45-minute exercise bout. At 8:00 AM,
after overnight fasting, a venous catheter was inserted
into the antecubital vein. A blood sample was collected
at the beginning and in the course (after 45-minute
exercise, after a 90-minute post-exercise recovering
phase) of the experiment to estimate plasma NPY, GH,
leptin, FFA, glycerol, insulin and blood glucose concen-
trations. Blood samples were collected into chilled tubes
containing Na2EDTA and antilysin. Plasma was sepa-
rated immediately by centrifugation at 4°C and stored at
-80°C until being assayed. Subjects started their 45-min
exercise alone or exercise after Aci administration,
assigned randomly 60 minutes before exercise once a
week over a total of 2 weeks. After the 45-min exercise,
all subjects assumed a resting supine position on a com-
fortable bed for additional 90 minutes.
Microdialysate sampling
The in situ and in vivo microdialysis technique was used
to examine the exercise-stimulated lipolysis (by measure-
ment of dialysate glycerol) alone or with the acute-bolus
Aci therapy randomly received (500 mg per os 1 hour
before a single exercise bout, Olbetam capsules, Farmita-
lia Carlo Erba, Milan, Italy) once a week over a total of 2
weeks. A CMA-60 microdialysis probe (CMA Microdia-
lysis, Stockholm, Sweden) with membrane length 3 cm
and molecular weight cut-off 20 kDa was inserted sc
under sterile conditions (8-10 cm left of the umbilicus at
least 60 min before microdialysate sampling). After inser-
tion of the CMA-60 catheter, perfusion with sterile
Ringer solution was started at a flow rate of 2 μl/min
using a CMA 107 microdialysis pump (CMA Microdialy-
sis, Stockholm, Sweden). Microdialysate samples were
collected every 30-45 min over a 6-hour period, 120 min
b e f o r et h ee x e r c i s e( a t4 5m i ni nterval-baseline values),
45 min during the exercise and at the last 45-min interval
before ending the 90-min post-exercise recovering phase.
The microdialysate volumes of samples measured at 45-
min intervals were 88 ± 3 μl. Microvials were placed on
ice immediatelly after the collection, and stored at -80°C
until analysis. Before starting microdialysis perfusion, the
relative glycerol recovery (RGR) was calculated in vitro at
a temperature of 37°C maintained by a digital block hea-
ter to simulate body temperature. Different perfusion
rates (0.1, 0.3, 0.5, 1.0, 2.0, 5.0 μl/min) were tested to
investigate possible relative recovery vs. perfusion rate
dependency. At each rate, RGR was calculated from 15
samples collected at perfusion rate-dependent intervals
according to the formula: RGR (%) = (glycerol concentra-
tion in dialysate/glycerol concentration in standard solu-
tion) × 100. A perfusion rate of 2 μl/min was selected for
in vivo microdialysis, based on the calculated in vitro
RGR corrected for experiment duration. The procedure
is described in detail in our previous report [34].
Hormonal and biochemical assays
NPY in plasma (200 μl) was determined by a commer-
cial RIA kit (Linco Research, Inc., St. Charles, Missouri,
USA). The intra- and interassay variability for plasma
NPY was 5.0% and 8.4%, respectively, sensitivity was 3
pmol/l. GH in plasma (50 μl) [as a 22 kDa monomeric
GH form and non-22 kDa isoforms (dimers and GH
bound to plasma proteins)] was measured by a commer-
cial RIA kit (Immunotech, Prague, Czech Republic).
Intra- and inter-assay variability was 1.5% and 14%,
respectively, sensitivity was 0.1 μIU/ml. Leptin in plasma
(200 μl) was measured by a commercial RIA kit (Linco
Research, St. Charles, Missouri, USA). Sensitivity, inter-
assay and intra-assay variability were 0.05 ng/ml, 8.6%
and 5.9%, respectively. Insulin in plasma (10 μl) and
blood glucose in plasma (10 μl) were measured in a
Cobas Integra 400 plus system (Roche Diagnostics,
GmbH, Mannheim, Germany). Glycerol in plasma (10
μl) and in the dialysate (10 μl) was analyzed with a
radiometric kit (Randox Laboratories, GY 105, Montpel-
lier, France). FFA in plasma (10 μl) were estimated col-
orimetrically with a commercial kit (Randox
Laboratories, FA 115, Montpellier, France). All assays
were run twice in duplicate.
Statistical analysis
All values are presented as the means ± S.E.M. All sta-
tistical comparisons were performed using General Lin-
ear Model consisting of subject factor, between-subject
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interactions Status × Aci and Status × Time. Correla-
tions between parameters were examined using Spear-
man’s rank correlation coefficient. The original data was
transformed by power transformations (individually for
each dependent variable) to attain Gaussian’s data distri-
bution and constant variance in the data and residuals.
T h eh o m o g e n e i t yo ft h ed a t aa f t e rp o w e rt r a n s f o r m a -
tions was tested by residual analysis. Absolute values of
Studentized residuals in transformed data were less than
3 for all variables and all experimental points. The dif-
ference between medians (Mann-Whitney and Wilcoxon
Rank-Sum tests) was applied to compare baseline values
with those during exercise. A P value < 0.05 denoted
statistical significance.
Results
Tables and figures
Baseline characteristics of the study subjects, including
anthropometric measurements, are summarized in Table
1. The exercise-induced changes of the study subjects
during Aci and placebo treatment in plasma and in AT
are shown in Table 2 Table 3 Figure 1, Figure 2 and 3,
respectively.
Correlations between parameters
The relationship of hormonal, biochemical and
anthropometric parameters during basal conditions in
patients with BN and healthy control women
Fasting plasma leptin levels correlated positively with
BMI in the controls (r =0 . 6 2 ,P = 0.03). Fasting plasma
blood glucose concentrations correlated negatively with
plasma FFA concentrations in BN (r = - 0.66, P =0 . 0 2 ) .
Fasting plasma glycerol concentrations correlated posi-
tively with plasma FFA concentrations in BN patients (r
= 0.69, P = 0.0001) and the controls (r =0 . 8 7 ,P =
0.0001).
The relationship of hormonal and biochemical parameters
after the exercise with Aci administration (45-minute) in
patients with BN and in healthy control women
Plasma GH concentrations correlated positively with
plasma NPY concentrations after 45-minute exercise
with Aci administration only in BN patients (r =0 . 5 6 ,P
= 0.01). Plasma glycerol concentrations correlated
positively with plasma FFA concentrations after 45-min-
ute exercise with Aci administration in BN patients (r =
0.91, P = 0.004) and the controls (r =0 . 9 3 ,P = 0.002).
Plasma insulin levels correlated positively with plasma
leptin levels after 45-minute exercise with Aci adminis-
tration in the controls (r = 0.64, P = 0.04). Plasma leptin
levels correlated positively with blood glucose concen-
trations after 45-minute exercise with Aci administration
in the controls (r =0 . 6 2 ,P = 0.03). Plasma FFA levels
correlated positively with plasma insulin levels after 45-
minute exercise with Aci administration in the controls
(r = 0.68, P = 0.02).
Baseline and exercise-induced plasma NPY concentrations
alone or together with Aci administration
Mean baseline fasting plasma NPY concentrations were
significantly increased in BN patients compared to the
controls Plasma NPY levels increased significantly after
the 45-minute exercise with placebo in both groups, but
the next week the administration of Aci 60 minutes
before the 45-minute exercise led to a further increase
of plasma NPY levels only in BN patients. Plasma NPY
levels decreased to the baseline values after a 90-minute
post-exercise recovering phase with placebo in both
groups, but less in BN patients if associated with Aci
administration compared to the controls (Table 2 Figure
1).
Baseline and exercise-induced plasma GH concentrations
alone or together with Aci administration
Mean baseline fasting plasma GH concentrations were
significantly increased in BN patients compared to the
controls. Plasma GH concentrations increased signifi-
cantly after the 45-minute exercise with placebo in both
groups. The next week the administration of Aci 60
minutes before the 45-minute exercise increased plasma
GH in both groups, more in BN patients. Plasma GH
levels decreased significantly more in the controls after
90 minutes of post-exercise recovering phase with pla-
cebo than in BN patients. On the contrary, plasma GH
levels were significantly el e v a t e da t9 0m i n u t e sa f t e r
post-exercise recovering phase with Aci administration
in both groups (Table 2 Figure 1).
Baseline and exercise-induced plasma FFA concentrations
alone or together with Aci administration
Mean baseline fasting plasma FFA concentrations were
similar in BN patients and the controls. Plasma FFA
concentrations increased significantly after 45-minute
exercise with placebo in both groups. Plasma FFA con-
centrations decreased significantly to the baseline levels
after 45-minute exercise with Aci administration in both
groups when compared to the exercise associated with
placebo. Plasma FFA concentrations approached the
baseline values after a 90-minute post-exercise recover-
ing phase with placebo in both groups. Plasma FFA con-
centrations decreased significantly under the baseline
Table 1 Anthropometric characteristics of the study
subjects (means ± S.E.M.).
C( n =8 ) B N( n =8 ) P value
Age (years) 25.83 ± 1.69 24.33 ± 1.38 NS
BMI (kg/m
2) 19.98 ± 0.44 20.63 ± 0.80 NS
%B F 24.50 ± 0.47 24.83 ± 1.92 NS
C = controls (n = 8); BN = bulimia nervosa (n = 8); BMI = body mass index; %
BF = percentage of body fat; NS = not significant; n = the number of subjects.
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parameters.
0 min 45 min 45 min 90 min 90 min
Basal Exercise Exercise Post-exercise Post-exercise
+ placebo + Aci + placebo + Aci
NPY (pmol/l)
C group (n = 8) 45 ± 2.3 69.7 ± 19.2** 69 ± 9.2** 45.6 ± 6.7 51.5 ± 12
BN group (n = 8) 53 ± 3.0
$ 78.3 ± 15.7**
$ 111.4 ± 20.6***
$+ 51.2 ± 8.6 65 ± 10.6
$
GH (mIU/l)
C group (n = 8) 7.1 ± 0,5 11.3 ± 2.2*** 40.9 ± 8.7**** 0.7 ± 0.2**** 21.4 ± 8.1****
BN group (n = 8) 11.2 ± 0.9
$ 13.1 ± 4.3*** 73.7 ± 23.1****
$ 2.01 ± 0.5****
$ 28.9 ± 7.5****
$
Leptin (ng/ml)
C group (n = 8) 7.83 ± 1.3 6.52 ± 0.68* 7.73 ± 1.13
+ 6.21 ± 0.75* 7.84 ± 0.94
#
BN group (n = 8) 6.96 ± 1.1
$ 6.31 ± 0.83* 6.8 ± 1.38
$+ 5.93 ± 0.69* 7.98 ± 0.99*
#
Insulin (mIU/l)
C group (n = 8) 4.32 ± 0.98 4.05 ± 0.37 2.66 ± 0.98*
+ 2.33 ± 0.34* 1.9 ± 0.8**
BN group (n = 8) 2.5 ± 0.59
$ 2.32 ± 0.71
$ 2.0 ± 0.33* 2.01 ± 0.5* 1.03 ± 0.44**
$#
Glucose (mmol/l)
C group (n = 8) 4.72 ± 0.11 4.8 ± 0.26 4.63 ± 0.19 4.59 ± 0.15 4.33 ± 0.23
BN group (n = 8) 4.33 ± 0.13 4.46 ± 0.38 5.03 ± 0.34*
+ 4.07 ± 0.3 4.43 ± 0.26
FFA (mmol/l)
C group (n = 8) 0.86 ± 0.3 1.54 ± 0.13**** 0.82 ± 0.05
+ 0.79 ± 0.05 0.25 ± 0.02****
#
BN group (n = 8) 0.79 ± 0.3 1.6 ± 0.28**** 0.79 ± 0.14
+ 0.83 ± 0.1 0.26 ± 0.02****
#
Glycerol (μmol/l)
C group (n = 8) 117 ± 33 318 ± 34**** 157.8 ± 18.4
++ 85 ± 7.3 44 ± 4.7**
#
BN group (n = 8) 82.2 ± 26
$ 256 ± 56****
$ 114 ± 13
$+++ 74 ± 4.2 57 ± 6.2**
$#
Values are means ± S.E.M. C = controls (n = 8), BN = bulimia nervosa (n = 8), n = the numbers of subjects are in brackets.
*=P < 0.05, ** = P < 0.01, *** = P < 0.001, **** = P < 0.0001 vs. resting (baseline) values
$ = P < 0.05 BN vs. control subjects (C)
+ = P < 0.05 exercise together with Aci administration vs. exercise alone, 45 minutes
++= P < 0.01 exercise together with Aci administration vs. exercise alone, 45 minutes
+++ = P < 0.001 exercise together with Aci administration vs. exercise alone, 45 minutes
# = P < 0.05 post-exercise recovering phase together with Aci administration vs. post-exercise recovering phase alone, 90 minutes
Effect of 45-min exercise (2 W/kg of lean body mass [LBM]) alone or together with Acipimox (Aci) administration on plasma adipose tissue (AT)-gut-brain
peptides, blood glucose, free fatty acids (FFA) and glycerol levels in the controls (C) (n = 8) and bulimia nervosa (BN) patients (n = 8).
Table 3 Effect of exercise alone or together with Acipimox administration on extracellular glycerol in adipose tissue.
0 min 45 min 45 min 90 min 90 min
Basal Exercise Exercise Post-exercise Post-exercise
+ placebo + Aci + placebo + Aci
Dialysate Glycerol (μmol/l)
C group (n = 8) 41.21 ± 4.43 82.2 ± 11.82**** 41.6 ± 4.21
++ 40.5 ± 3.81 33.9 ± 3.16**
#
BN group (n = 8) 36.39 ± 4.15
$ 148.6 ± 23.2****
$$ 38.3 ± 5.39
++++ 29.0 ± 2.9
$ 20.4 ± 3.01**
$#
** = P < 0.01 vs. resting (baseline) values
**** = P < 0.0001 vs. resting (baseline) values
$ = P < 0.05 BN vs. control subjects (C)
$$ = P < 0.01 BN vs. control subjects (C)
++ = P < 0.01 exercise together with Aci administration vs. exercise alone, 45 minutes
++++ = P < 0.0001 exercise together with Aci administration vs. exercise alone, 45 minutes
# = P < 0.05 post-exercise recovering phase together with Aci administration vs. post-exercise recovering phase alone, 90 minutes
Dialysate glycerol concentration in subcutaneous (sc) abdominal adipose tissue (AT) during baseline conditions (microvials with interstitial fluid samples were
collected at 45-min intervals), during exercise (at 45-min interval, 2 W/kg of lean body mass [LBM]), and at the last 45-min interval before ending 90-min post-
exercise recovering phase alone or together with Acipimox (Aci) administration in the controls (C) (n = 8) and bulimia nervosa patients (BN) (n = 8). Values are
means ± S.E.M. n = the number of subjects.
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Figure 1 Effect of exercise alone or together with Acipimox administration on plasma NPY, GH and FFA levels.
$P <0 . 0 5v s .c o n t r o l
subjects (C), p.o., per os. **P < 0.01, ***P < 0.001, ****P < 0.0001 vs. resting (baseline) values.
+P < 0.05 exercise together with Aci administration
vs. exercise alone, 45 minutes.
#P < 0.05 post-exercise recovering phase together with Aci administration vs. post-exercise recovering phase
alone, 90 minutes. Effect of 45-min exercise (2 W/kg of lean body mass [LBM]) alone or together with Acipimox (Aci) administration on plasma
neuropeptide Y (NPY), growth hormone (GH) and free fatty acids (FFA) levels (means ± S.E.M.) in the controls (C) (n = 8) and bulimia nervosa
(BN) patients (n = 8).
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Figure 2 Effect of exercise alone or together with Acipimox administration on plasma and dialysate glycerol levels.
$P <0.05 BN vs.
control subjects (C), p.o., per os.
$$P < 0.01 BN vs. control subjects (C). **P < 0.01, ****P < 0.0001 vs. resting (baseline) values.
++ P < 0.01 exercise
together with Aci administration vs. exercise alone, 45 minutes.
+++P < 0.001 exercise together with Aci administration vs. exercise alone, 45
minutes.
++++P < 0.0001 exercise together with Aci administration vs. exercise alone, 45 minutes.
#P < 0.05 post-exercise recovering phase
together with Aci administration vs. post-exercise recovering phase alone, 90 minutes. Effect of 45-min exercise (2 W/kg of lean body mass
[LBM]) alone or together with Acipimox (Aci) administration on plasma glycerol and dialysate glycerol levels (means ± S.E.M.) in the controls (C)
(n = 8) and bulimia nervosa (BN) patients (n = 8).
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Figure 3 Effect of exercise alone or together with Acipimox administration on plasma leptin and insulin levels.
$P < 0.05 vs. control
subjects (C), p.o., per os. *P < 0.05, **P < 0.01 vs. resting (baseline) values.
+P < 0.05 exercise together with Aci administration vs. exercise alone,
45 minutes.
#P < 0.05 post-exercise recovering phase together with Aci administration vs. post-exercise recovering phase alone, 90 minutes.
Effect of 45-min exercise (2 W/kg of lean body mass [LBM]) alone or together with Acipimox (Aci) administration on plasma leptin and insulin
levels (means ± S.E.M.) in the controls (C) (n = 8) and bulimia nervosa (BN) patients (n = 8).
Smitka et al. Nutrition & Metabolism 2011, 8:81
http://www.nutritionandmetabolism.com/content/8/1/81
Page 9 of 14values after 90 minutes of post-exercise recovering
phase with Aci administration in both groups (Table 2
Figure 1).
Baseline and exercise-induced plasma glycerol
concentrations alone or together with Aci administration
Mean baseline fasting plasma glycerol levels were signifi-
cantly decreased in BN patients compared to the controls
Plasma glycerol levels increased significantly after 45-min-
ute exercise with placebo in both groups. Plasma glycerol
concentrations approached the baseline values after 90
minutes of post-exercise recovering phase with placebo in
both groups. Plasma glycerol levels decreased significantly
after 45-minute exercise with Aci administration more in
BN patients when compared to the exercise associated
with placebo. Plasma glycerol concentrations significantly
decreased under the baseline values after 90 minutes of
post-exercise recovering phase with Aci administration in
both groups (Table 2 Figure 2).
Baseline and exercise-induced AT glycerol concentrations
alone or together with Aci administration
Mean baseline AT glycerol levels were significantly
decreased in BN patients compared to the controls. AT
glycerol concentrations increased significantly after 45-
minute exercise with placebo more in BN patients. AT
glycerol levels decreased significantly to the baseline
values after 45-minute exercise with Aci administration
in both groups when compared to the exercise asso-
ciated with placebo. AT glycerol concentrations
approached the baseline values after 90 minutes of post-
exercise recovering phase with placebo in the controls,
while AT glycerol concentrations decreased under the
baseline values in BN patients. AT glycerol levels
decreased significantly under the baseline levels after 90
minutes of post-exercise recovering phase with Aci
administration in both groups (Table 3 Figure 2).
Baseline and exercise-induced plasma leptin concentrations
alone or together with Aci administration
Mean baseline fasting plasma leptin levels were signifi-
cantly decreased in BN patients compared to the con-
trols. Plasma leptin levels decreased significantly after
45-minute exercise with placebo in both groups. Plasma
leptin concentrations approached the baseline values
after 45-minute exercise with Aci administration in both
groups. Plasma leptin concentrations decreased signifi-
cantly after 90 minutes of post-exercise recovering
phase with placebo in both groups. Plasma leptin levels
increased significantly after 90 minutes of post-exercise
recovering phase with Aci administration in both groups
when compared to the post-exercise recovering phase
associated with placebo (Table 2 Figure 3).
Baseline and exercise-induced plasma insulin
concentrations alone or together with Aci administration
Mean baseline fasting plasma insulin concentrations
were significantly decreased in BN patients compared to
the controls. Plasma insulin concentrations approached
the baseline values after 45-minute exercise with placebo
in both groups. The next week the administration of Aci
60 minutes before the 45-minute exercise decreased sig-
nificantly plasma insulin in both groups. Plasma insulin
levels decreased significantly after 90 minutes of post-
exercise recovering phase with placebo in both groups.
Plasma insulin levels decreased significantly after 90
minutes of post-exercise recovering phase with Aci
administration more in BN patients (Table 2 Figure 3).
Baseline and exercise-induced plasma blood glucose
concentrations alone or together with Aci administration
Mean baseline fasting plasma blood glucose concentra-
tions were similar in BN patients and the controls.
Plasma blood glucose levels were over the baseline
values after 45-minute exercise with placebo in both
groups. Plasma blood glucose levels increased signifi-
cantly after 45-minute exercise with Aci administration
in BN patients. Plasma blood glucose levels were under
the baseline values after 90 minutes of post-exercise
recovering phase with placebo in both groups. Plasma
blood glucose levels approached the baseline values after
90 minutes of post-exercise recovering phase with Aci
administration in both groups (Table 2).
Discussion
In the present study, basal fasting NPY and GH plasma
levels were increased and independent of BMI in BN
patients, and were similarly increased after acute exer-
cise (45-minute) with placebo in both groups. The
important finding of the present study is that anti-lipo-
lytic drug Aci administered 60 minutes before initiating
short-term exercise induced further important increase
of plasma NPY levels only in BN patients, and further
increase of plasma GH levels in both groups, more in
BN patients. Further, we found that basal fasting leptin
plasma levels decreased in BN patients, and were simi-
larly decreased after acute exercise (45-minute) with pla-
cebo in both groups. Importantly, anti-lipolytic drug Aci
during short-term exercise not only prevented any fall-
ing of plasma leptin levels in both groups, but even
increased plasma leptin in the post-exercise recovering
phase (90 minutes) with Aci administration, more in BN
patients.
Orexigenic hypothalamic peptide NPY participates in
leptin, ghrelin and GH regulation pathways [35]. The
molecular mechanisms by which acute exercise or anti-
lipolytic drugs could cause an increase in plasma NPY
and GH are not clear. It was demonstrated that ghrelin
action can be modulated by NPY [36,37]. Until now, the
neuroendocrine control of NPY secretion during exer-
cise is still unknown. Thus, induced changes in NPY
and GH may be working through divergent signal trans-
duction pathways or receptor array [10,11,38-42]. Very
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gic pathway is involved in the mechanism connecting
physical exercise to NPY secretion.
In our present study, exercise induced an increase in
plasma NPY levels in the controls and in BN women in
whom the NPY increase was higher, without exhibiting
any significant dependence on plasma leptin and ghrelin
levels and on plasma glycerol and FFA concentrations
[16]. These results may indicate a disorder of the gut-
hypothalamic-AT pathway in these patients in order to
prevent energy losses. Hence, post-exercise decrease of
leptin and increase of NPY are probably part of adaptive
mechanisms leading to conservation of energy storage in
BN [16,44].
The exercise plus Aci-administration further increased
plasma NPY and GH levels more in BN patients. Thus,
elevated NPY and GH levels induced by exercise
together with Aci do not appear to be directly mediated
via FFA, and to influence ghrelin secretion in both
groups, indicating that FFA probably are not ghrelin
enhancers [16]. Interestingly, plasma GH levels after 45-
minute exercise with Aci administration positively corre-
lated with plasma NPY levels only in BN patients and
these observations lead us to suggesting that GH can be
responsible for the increase of NPY production [38].
Kos et al [4] demonstrated that NPY is expressed and
secreted by human adipocytes. Moreover, NPY is co-
localizated with norepinephrine in perivascular sympa-
thetic nerves, and it can be assumed that the exercise-
induced increase in plasma NPY can be associated with
increased norepinephrine in AT [22]. These findings are
in accordance with previous and recent reports suggest-
ing higher activity of SNS in AT and disrupted adrener-
gic regulation of lipolysis observable in both receptor
and postreceptor levels in sc abdominal AT in AN
[45,46]. It has been shown by numerous studies that
SNS can exert tonic inhibitory action on leptin secre-
tion, and that adrenergic regulation may contribute to
rapid decrease both of plasma insulin and leptin levels
during exercise [44,47].
In the present study, we found significantly decreased
both baseline plasma leptin and insulin levels in BN
patients similarly as documented in AN patients [44,48].
Plasma leptin levels were significantly lower immediately
after exercise (45-minute) and after the post-exercise
recovering phase (90-minute) combined with placebo in
both groups. On the other hand, plasma FFA levels
were significantly increased immediately after exercise
(45-minute), and after the post-exercise recovering
phase (90-minute) associated with placebo the values
approached the baseline ones in both groups. This may
provide evidence that FFA are not involved in the exer-
cise-induced leptin decrease. Furthermore, after the
post-exercise recovering phase (90-minute) with placebo,
a decrease in plasma insulin levels was observed in both
groups.
The role of plasma leptin and FFA levels in exercise
has not been defined. A negative correlation was found
between plasma FFA and leptin levels [23] and it was
suggested that lipolysis may explain the rapid leptin
decrease after the exercise, although Gomez-Merino et
al [47] failed to find any correlation between plasma lep-
tin levels and plasma FFA levels after physical activity in
humans. Moreover, treatment with Aci increased signifi-
cantly plasma leptin levels in humans [49,50]. These
observations led us to suggest that administration of Aci
might prevent the drop of plasma leptin levels during
short-term exercise in both groups; in addition, after the
90-minute post-exercise recovering phase with Aci
administration plasma leptin levels increased signifi-
cantly more in BN patients.
After the 45-minute exercise, GH and blood glucose
concentrations were more expressed in the presence of
Aci vs. placebo in BN patients, and plasma insulin levels
were lower after the post-exercise recovering phase (90-
minute) combined with Aci administration, more in BN
patients. It has been shown that anti-lipolytic Aci may
decrease insulin and increase blood glucose concentra-
tions [51]. Thus, GH and Aci administration during exer-
cise promote glucose production, and increased plasma
blood glucose may also stimulate leptin secretion [50]. In
our present study, plasma leptin levels correlated posi-
tively with blood glucose concentrations after 45-minute
exercise with Aci administration in the controls. Like-
wise, Lissett et al [52] demonstrated that a single bolus of
GH increases plasma leptin levels in humans.
Furthermore, we observed lower levels of both base-
line AT and plasma glycerol in patients with BN when
compared to age- and weight-matched healthy women.
Some authors did not observe changed baseline plasma
and AT glycerol concentrations in AN patients with low
BMI compared to the controls [22,44] but others found
higher local glycerol concentrations in AT of under-
weight patients with AN [46]. Likewise, under in vivo
conditions, we found that the sensitivity of beta-adrener-
gic receptors to norepinephrine in sc abdominal AT is
decreased in patients with AN. This may be due to
changed SNS in sc abdominal AT that results in down-
regulation of beta-receptors and therefore to decreased
lipolysis to protect fat stores from further depletion by
increased sympathetic nervous activity [22]. In agree-
ment with this report, Dostalova et al [53] revealed nor-
mal dialysate leptin concentrations in sc abdominal AT
in AN patients. One explanation of this may be a
reduced efficiency of both the SNS and NPY inhibiting
adipocyte leptin production in AN.
The lipolytic effect of GH is one of the most impor-
tant actions of GH favoring the use of FFA as an energy
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the HSL and indirectly, lowering the ability of adipo-
cytes to respond to alpha2-adrenergic dependent inhibi-
tion of cAMP production [54]. Importantly, we found a
discrepancy between overall (plasma) glycerol and local
(dialysate) glycerol levels in BN patients, and we deter-
mined a significantly higher dialysate glycerol level dur-
ing exercise in BN compared to the controls. Currently,
it is well known that local (tissue) lipolysis does not
reflect plasma glycerol levels during exercise in BN
patients [22,45]. This discrepancy could be possibly
explained by the fact that plasma glycerol concentration
reflects the net amount of this parameter released from
different sources, whereas dialysate glycerol concentra-
tion determines the quantity released in AT. Aci acutely
received during the exercise led to much more abolished
lipolysis in sc abdominal AT in BN than in the controls,
which leads us to suggesting that altered lipolysis in BN
may result from local modification of both adrenergic
and NPY-ergic activities. Interestingly, the effect of Aci
administration on higher epinephrine secretion was
observed in obese and lean males [51]. Thus, Aci, cate-
cholamines and NPY act via their inhibition of cAMP
production in AT, rather than via alternative cAMP-
independent pathways [25,30-32], and up-regulation of
receptor subtypes and/or their sensitivity or affinity are
much more effective in abolishing lipolysis in BN.
Furthermore, we found even higher plasma glycerol
levels after the exercise combined with Aci administra-
tion in the controls. These observations led us to sug-
gesting that glycerol is not easily remetabolized, hence
stays behind and its level therefore increases, and that
t h ed e c r e a s eo fp l a s m aF F Al e v e l st ob a s a lv a l u e si s
exerted by facilitated turnover of FFA in BN. Unexpect-
edly, we did not confirm that increased plasma FFA
levels inhibit lipolysis via a feedback mechanism [55].
Conclusions
Taken together, it can be concluded, based on this sin-
gle-blind, placebo-controlled, randomized, microdialysis
study that anti-lipolytic drug Aci during exercise (45-
minute) further increases plasma NPY, GH and leptin
levels (after 90 minutes of post-exercise recovering
phase) in BN patients and leads to lipolysis abolished to
a much higher extent in sc abdominal AT in BN. Thus,
it appears that bulimic patients are very sensitive to
negative caloric balance and acute administration of Aci,
and show hyperreactive responses both in NPY, GH and
leptin; these data establish NPY, GH and leptin as valid
biomarkers of BN [16,28,29,44]. Our results support the
hypothesis that elevated NPY and GH levels induced by
the exercise together with Aci administration thus do
not appear to be directly mediated via FFA and that
exercise- and Aci-induced leptin releases are not
mediated by FFA. Thus, these observations lead us to
suggesting that Aci exerts an effect on a FFA-indepen-
dent mechanism. Altogether, our results support the
hypothesis that Aci acts via its inhibition of cAMP pro-
duction in sc abdominal AT, rather than via alternative
cAMP-independent pathways. In addition, the exercise
induced similar increases in plasma glycerol levels in
both groups while the exercise with Aci administration
resulted in a stronger plasma glycerol decrease in BN
patients. Thus, plasma glycerol is not easily remetabo-
lized, and the decrease of plasma glycerol after the exer-
cise associated with Aci administration could be exerted
by facilitated turnover of plasma glycerol, which would
reflect abnormal metabolic status in this eating disorder.
Lower basal lipolysis in AT in BN patients may be due
to a protective mechanism that prevents the exhaustion
of energy reserves.
Endocrine perturbations and a dysfunction within the
FFA-leptin-NPY-GH system may also take part in the
etiopathogenesis of either bulimia or AN. Better under-
standing of the role of NPY and leptin agonists or inhi-
bitors and their interactions with adipocyte lipolysis and
the GH neuroendocrine axis may provide an entirely
new therapeutic approach in treatment of BN and AN
patients who poorly respond to various pharmacological
therapies.
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